Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial.

摘要: BACKGROUND The 46,193 men aged 45 to 80 years registered in the electoral roll of Quebec City and its Metropolitan area were randomized November 1988 between screening no a study aimed assessing impact prostate cancer on cause-specific death. METHODS At first visit, included measurement serum prostatic specific antigen (PSA) using 3.0 ng/ml as upper limit normal digital rectal examination (DRE). Transrectal echography (TRUS) was performed only if PSA and/or DRE abnormal biopsy then done, above predicted value. At follow-up visits, alone used prescreening. RESULTS 137 deaths due occurred 1989 1996, inclusively, 38,056 unscreened while 5 observed among 8,137 screened individuals. The death rates during eight-year period 48.7 15 per 100,000 man-years groups, respectively, for 3.25 odds ratio favor early treatment (P < 0.01). CONCLUSIONS If is started at age 50 (or higher risk population), annual or biannual highly efficient identify who are high having cancer. Coupled with localized disease, this approach demonstrates, time, that diagnosis permits dramatic decrease from Prostate 38:83–91, 1999. © 1999 Wiley-Liss, Inc.